Merdury Biopharmaceutical EBITDA TCAC 3A

Que fait Merdury Biopharmaceutical ? Merdury Biopharmaceutical Corp is a pharmaceutical company based in Taipei, Taiwan, operating within the Health Care sector. The company has a small workforce of 13 employees and went public on December 23, 2022, with its ticker listed as 6932.TWO. Merdury Biopharmaceutical Corp focuses on developing drugs that address unmet medical needs, difficult generic drugs, and second-class new drugs. The company utilizes a self-developed drug development platform called StackDose, which enables the creation of tablets with controlled dissolution properties, allowing for either immediate or sustained drug release. This technology supports the development of products such as Sildenafil, Metformin, Tadalafil, Zolpidem, angina treatments, migraine medications, and multi-ingredient antihypertensive drugs. These products are primarily marketed and sold in Taiwan and the United States. The company's website is https://merdury.com, providing further information about its operations and offerings. Merdury Biopharmaceutical Corp operates as a publicly traded entity with a focus on innovative pharmaceutical solutions within the Taiwanese and U.S. markets. Merdury Biopharmaceutical est l'une des entreprises les plus populaires sur Eulerpool.